Biogen (BIIB) PEG Ratio: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$211.32-1.19 (-0.56%)

Delayed quote: Sep 9, 2026, 10:35 AM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.22B	N/A	N/A	0.24	0.23
Centene Corp. (CNC)vs ›	$31.70B	N/A	0.18	0.16	0.16
DexCom, Inc. (DXCM)vs ›	$31.97B	0.67	19.51	10.66	8.56
ResMed Inc. (RMD)vs ›	$31.77B	2.00	1.36	1.79	1.56
Zoetis Inc. (ZTS)vs ›	$30.75B	2.04	2.96	3.83	3.78
Waters Corporation (WAT)vs ›	$30.60B	75.61	75.61	40.77	27.51
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.01B	4.14	2.27	2.27	1.52
Medline Inc. (MDLN)vs ›	$29.41B	N/A	0.07	0.07	0.07
Alcon Inc. (ALC)vs ›	$33.52B	N/A	5.21	5.21	4.55
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$33.94B	N/A	1.85	3.49	3.16

NAME

MARKET CAP

PEG RATIO

TTM

Biogen Inc. (BIIB)

$31.22B

N/A

0.24

0.23

Centene Corp. (CNC)vs ›

$31.70B

N/A

0.18

0.16

DexCom, Inc. (DXCM)vs ›

$31.97B

0.67

19.51

10.66

8.56

ResMed Inc. (RMD)vs ›

$31.77B

2.00

1.36

1.79

1.56

Zoetis Inc. (ZTS)vs ›

$30.75B

2.04

2.96

3.83

3.78

Waters Corporation (WAT)vs ›

$30.60B

75.61

40.77

27.51

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.01B

4.14

2.27

1.52

Medline Inc. (MDLN)vs ›

$29.41B

N/A

0.07

Alcon Inc. (ALC)vs ›

$33.52B

N/A

5.21

4.55

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$33.94B

N/A

1.85

3.49

3.16

PEG Ratio FAQ

What is the PEG ratio for Biogen Inc. (BIIB)?

The PEG ratio for BIIB stock is N/A.

What is the 3Y average PEG ratio for Biogen Inc. (BIIB)?

The 3Y average PEG ratio for BIIB stock is 0.24.

What is the 5Y average PEG ratio for Biogen Inc. (BIIB)?

The 5Y average PEG ratio for BIIB stock is 0.23.

What is the 10Y average PEG ratio for Biogen Inc. (BIIB)?

The 10Y average PEG ratio for BIIB stock is 0.54.

What is the 15Y average PEG ratio for Biogen Inc. (BIIB)?

The 15Y average PEG ratio for BIIB stock is 0.74.

What is the 20Y average PEG ratio for Biogen Inc. (BIIB)?

The 20Y average PEG ratio for BIIB stock is 0.65.

DATE	PEG RATIO
2024-12-31	0.34
2022-12-31	0.13
2019-12-31	0.21
2018-12-31	0.17
2016-12-31	1.63
2015-12-31	0.84
2014-12-31	0.47
2013-12-31	1.00
2012-12-31	1.81
2011-12-31	0.78
2010-12-31	0.93
2009-12-31	0.61
2008-12-31	0.55
2007-12-31	0.13
2006-12-31	2.31
2005-12-31	0.16
2003-12-31	0.02
2000-12-31	1.59
1999-12-31	0.32
1998-12-31	0.82
1997-12-31	0.52
1996-12-31	1.06

DATE

PEG RATIO

2024-12-31

0.34

2022-12-31

0.13

2019-12-31

0.21

2018-12-31

0.17

2016-12-31

1.63

2015-12-31

0.84

2014-12-31

0.47

2013-12-31

1.00

2012-12-31

1.81

2011-12-31

0.78

2010-12-31

0.93

2009-12-31

0.61

2008-12-31

0.55

2007-12-31

0.13

2006-12-31

2.31

2005-12-31

0.16

2003-12-31

0.02

2000-12-31

1.59

1999-12-31

0.32

1998-12-31

0.82

1997-12-31

0.52

1996-12-31

1.06

PEG Ratio: N/A

BIIB PEG Ratio Chart

BIIB Average PEG Ratio Chart

BIIB PEG Ratio Metrics

BIIB Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

PEG Ratio FAQ

BIIB PEG Ratio History

Related Metrics